Phase 2 N=31 MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Ovarian Carcinoma
Primary: Combined Best Overall Response Rate Based on Investigator Assessment — 0; 12 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=400 A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
MENINGOCOCCAL INFECTION
Primary: Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titers >= Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria…
Phase 2 N=98 Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
HIV-1 Infection
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL as Determined by the FDA-defined Snapshot Algorithm. — 96.9; 93.9 percentage of participants — p=0.5
Phase 2 N=131 A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve
Infertility · Ovulation Induction
Primary: Mean Number of Metaphase II (M-II) Oocytes Retrieved — 6.7; 7.0 M-II oocytes
Phase 2 N=30 Treatment of Rett Syndrome With Recombinant Human IGF-1
Rett Syndrome
Primary: Rett Syndrome Behavior Questionnaire (RSBQ) - Fear/Anxiety Subscale — 4.00; 5.00; 5.00; 3.00 units on a scale
Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
Phase 2 N=688 Postoperative Ibuprofen and the Risk of Bleeding After Tonsillectomy With or Without Adenoidectomy
Tonsillectomy · Adenoidectomy
Primary: Number of Participants With Level 3 Postoperative Hemorrhage — 10; 4 Participants
Phase 2 N=10 Risperidone and Desipramine in Alcohol Use and Schizophrenia
Schizophrenia · Alcoholism · Dual Diagnosis
Primary: Timeline Followback Assessing Number of Drinks Per Week — 35.9 Drinks per week — p=0.317
Phase 2 N=82 Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan
Multiple Myeloma
Primary: Objective Response Rate (ORR) of Participants Treated With Elotuzumab + Lenalidomide/Dexamethasone (E-Ld) — 87.5 Percentage of participants
Phase 2 N=14 Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Colorectal Cancer
Primary: Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) — 100 percentage of successful treatments
Phase 2 N=196 Study Evaluating Ibuprofen 600 mg Extended Release (ER) For Dental Pain
Pain
Primary: Time-weighted Sum of Pain Intensity Difference Score From 0 to 12 Hours (SPID 0-12) — 0.05; 16.87; 17.34; 12.66 units on a scale — p=<0.001
Phase 2 N=26 Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
Central Neuropathic Pain · Allodynia · Spinal Cord Injury
Primary: Percent Change in Peak Pain Intensity — -2.5; -7.9; -11.2; -19.2 percentage change from baseline — p=0.0322
Phase 2 N=398 A Study of LY2484595 in Patients With High LDL-C or Low HDL-C
Dyslipidemia
Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…
Phase 2 N=31 Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Episodes of Grade 3-4 Non Infectious, Non-dermatological or Non-neurological Toxicities, Episodes of Any Infections, Grade 3-4 Dermatological or Episodes of Grade 2-3…
Phase 2 N=136 Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix
Carcinoma of the Appendix · Primary Peritoneal Cavity Cancer
Primary: The Difference in the Number of Grade 3 or 4 Hematologic Toxicities (Leukopenia, Thrombocytopenia, and Neutropenia) Between the Mitomycin C and Oxaliplatin Treatments…